Articles tagged "Screening"

2019 American Transplant Congress
Liquid Biopsy for Chronic Rejection after Kidney Transplantation. A Novel Non-Invasive Biomarker Involved in Inflammatory Amplifier
Y. Takada¹, D. Kamimura², H. Higuchi¹, D. Iwami¹, K. Hotta¹, N. Iwahara¹, N. Shinohara¹, M. Murakami²
¹Renal and Genitourinary Surgery, Hokkaido University Hospital, Sapporo, Japan, ²Molecular Psychoimmunology, Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
*Purpose: In kidney transplantation (KTx), despite recent advances of medical technology, chronic rejection accounts for 25% of the graft loss. Chronic active antibody-mediated rejection (CAAMR)…
2019 American Transplant Congress
Outcomes for Lung Transplantation Recipients with Non-Alcoholic Fatty Liver Disease
A. J. Trindade¹, P. Burkett¹, S. El-Chemaly¹, N. Hashemi², T. Thaniyavarn¹, H. R. Mallidi³, H. J. Goldberg¹
¹Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, ²Gastroenterology and Hepatology, Brigham and Women's Hospital, Boston, MA, ³Division of Thoracic and Cardiovascular Surgery, Brigham and Women's Hospital, Boston, MA
*Purpose: Non-alcoholic Fatty Liver Disease (NAFLD) afflicts ~20-40% people in the western world and is a risk factor for comorbidities prevalent in the lung transplant…
2019 American Transplant Congress
Illustration of Renal Recovery in SLK with Utilization of Most Recent Allocation Criteria
B. Patel, R. Prashar, A. Babu
Henry Ford Hospital Detroit, Detroit, MI
*Purpose: Single Center review of Renal recovery in Simultaneous Liver Kidney Transplantation (SLKT) in patients who were approved for SLK based on the recent UNOS…
2019 American Transplant Congress
Frailty is Highly Prevalent in Lung Transplant Candidates and Varies by Frailty Tool
A. O'Boye, K. Leitner, M. Kelly, J. Wright, J. Lee, M. Sala, R. Tomic, S. Bhorade
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Lung transplantation is a lifesaving therapy in patients with advanced lung disease. However, frail lung transplant candidates are more likely to be delisted or…
2019 American Transplant Congress
Liver Transplant Centers Select Different Characteristics for Recipients and Deceased Donors: Implications for Patients When Choosing a Center
C. R. Schaffhausen¹, M. J. Bruin², S. Chu², D. Schladt¹, S. Chinnakotla³, J. R. Lake⁴, W. Kim⁵, S. W. Biggins⁶, J. J. Snyder⁷, B. L. Kasiske⁷, A. K. Israni¹
¹Hennepin Healthcare Research Institute, Minneapolis, MN, ²College of Design, University of Minnesota, Minneapolis, MN, ³Department of Surgery, University of Minnesota, Minneapolis, MN, ⁴Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, MN, ⁵Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, ⁶Division of Gastroenterology, University of Washington, Seattle, WA, ⁷Scientific Registry of Transplant Recipients, Minneapolis, MN
*Purpose: When patients can choose the liver transplant center at which to establish care, a prior knowledge of center acceptance practices (of candidates and donors)…
2019 American Transplant Congress
Introduction of Universal Hepatitis E RNA Screening in Deceased Organ Donors – The UK Experience
I. Ushiro-Lumb¹, K. Tettmar¹, I. Johannessen², K. Simpson², I. Hart³, J. Timms⁴, A. Hale⁵, S. Ijaz⁶, R. Tedder⁶, J. Forsythe¹
¹NHS Blood and Transplant, London, United Kingdom, ²Royal Infirmary of Edinburgh, Edinburgh, United Kingdom, ³Royal Liverpool University Hospital, Liverpool, United Kingdom, ⁴University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ⁵Public Health England, Leeds, United Kingdom, ⁶Public Health England, London, United Kingdom
*Purpose: We aim to describe the strategy and initial results of post-donation, universal screening of deceased organ donors in the UK. HEV RNA is tested…
2019 American Transplant Congress
Preoperative Risk Factor-based Cardiac Catheterization Is Associated With Low Cardiac Morbidity And Mortality In Liver Transplant Patients
R. Rachwan¹, I. Kutkut¹, P. D. Bourdillon², L. R. Timsina³, M. Ghabril⁴, C. A. Kubal⁵, M. A. Lacerda⁶, R. S. Mangus⁵
¹Internal Medicine, Indiana University, Indianapolis, IN, ²Internal Medicine, Indiana University, Division of Cardiology, Indianapolis, IN, ³Department of Biostatistics, Indiana University, Indianapolis, IN, ⁴Internal Medicine, Indiana University, Division of Hepatology, Indianapolis, IN, ⁵Surgery, Transplant Division, Indiana University, Indianapolis, IN, ⁶Internal Medicine, Division of Hepatology, Indiana University, Indianapolis, IN
*Purpose: Mortality post-liver transplant historically was largely attributed to coronary artery disease (CAD). Current guidelines recommend screening with non-invasive modalities in patients with risk factors.…
2019 American Transplant Congress
Screening for Renal Cell Masses in Kidney Transplant
H. E. Fernandez, D. Tsapepas, D. J. Cohen, M. Sumit, L. E. Ratner
Columbia University MC, New York, NY
*Purpose: End-stage renal disease (ESRD) is a risk factor for development of acquired cystic kidney disease (ACKD) with the incidence of ACKD rising from 90%…
2019 American Transplant Congress
Dobutamine Stress Echocardiography is a Poor Predictor of Clinically Significant Coronary Artery Disease in Patients Undergoing Liver Transplant Evaluation
D. L. Hughes¹, J. Rice¹, J. R. Burton¹, E. A. Pomfret², J. J. Pomposelli², A. V. Ambardekar³, S. M. Mandell⁴, M. S. Kriss¹
¹Division of Gastroenterology & Hepatology, University of Colorado School of Medicine (UCSOM), Aurora, CO, ²Division of Transplant Surgery, UCSOM, Aurora, CO, ³Division of Cardiology, UCSOM, Aurora, CO, ⁴Department of Anesthesiology, UCSOM, Aurora, CO
*Purpose: Given the high incidence of major cardiac events in the first year post-liver transplantation (LT) (>30%), the aim of this study was to determine…
2019 American Transplant Congress
Inflammation and Fibrosis Are Observed in 34% of Clinically Stable Adult Liver Transplant Recipients
L. Sun¹, J. Levitsky², S. Feng³, A. Humar⁴, A. J. Demetris⁴, J. Emond⁵, A. Shaked⁶, G. Klintmalm⁷, K. Mason⁸, M. DesMarais¹, A. Priore⁹, N. Bridges⁹, B. E. Burrell¹⁰, S. Chandran³, J. Markmann¹¹
¹ITN, San Francisco, CA, ²Northwestern, Chicago, IL, ³UCSF, San Francisco, CA, ⁴UPMC, Pittsburg, PA, ⁵Columbia, New York, NY, ⁶UPenn, Philadelphia, PA, ⁷Baylor, Dallas, TX, ⁸Rho, Chapel Hill, NC, ⁹NIAID, Bethesda, MD, ¹⁰ITN, Bethesda, MD, ¹¹MGH, Boston, MA
*Purpose: OPTIMAL is a 7-center immunosuppression withdrawal (ISW) study in non-autoimmune, non-HCV adult liver transplant recipients ≥3 yrs post-transplant (tx) (NCT02533180). Subjects underwent a screening…

« Previous Page
1
…
7
8
9
10
11
…
16
Next Page »